Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro

American Journal of Respiratory Cell and Molecular Biology

Volumn 19, Issue 3, 1998, Pages 477-484

  Wieslander, Elisabet ^a   Delander, E L ^a   Jarkelid L ^a   Hjertberg, E ^a   Tunek, A ^a   Brattsand, R ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; BUDESONIDE; FATTY ACID; FLUTICASONE; GLUCOCORTICOID; TRANSCRIPTION FACTOR AP 1;

ANIMAL; ARTICLE; CELL LINE; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KINETICS; METABOLISM; PHYSIOLOGY; RAT; REPORTER GENE;

ANDROSTADIENES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CELL LINE; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; FATTY ACIDS; GENE EXPRESSION REGULATION; GENES, REPORTER; GLUCOCORTICOIDS; KINETICS; RATS; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 0032158790     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.19.3.3195     Document Type: Article

References (32)

1. Brattsand, R., and B. Axelsson. 1997. Basis of airway selectivity of inhaled glucocorticoids. In Inhaled Glucocorticoids in Asthma, Mechanisms and Clinical Actions (Vol. 97, Lung Biology in Health and Disease Series). R. P. Schleimer, W. W. Busse, and P. M. O'Byrne. editors. Marcel Dekker, Inc., New York. 351-379.
2. Würthwein, G., S. Rehder, and P. Rodhewald. 1992. Lipophilicity and receptor affinity of glucocorticoids. Pharm. Ztg. Wis. 137: 161-167.
3. Högger, P., and P. Rodhewald. 1994. Binding kinetics of fluticasone propionate to the human glucoeorticoid receptor. Steroids 59: 597-602.
4. Tunek, A., K. Sjödin, and G. Hallström. 1997. Reversible formation of fatty acid esters of budesonide. an anti-asthma glucocortieoid, in human lung and liver microsomes. Drug Metabol. Dispos. 25: 1311-1317.
5. Miller-Larsson, A., H. Mattsson, E. Hjertberg, A. Tunek, and R. Brattsand. 1998. Reversible fatty acid conjugation of budesonide: a novel mechanism for prolonged retention of topical steroid in asthmatic tissue. Drug Metab. Dispos. Biol. Fate Chem. (In press)
6. Miller-Larsson, A., H. Mattsson, S. Ohlsson, E. Hjertberg, A. Tunek, M. Dahlbäck. and R. Brattsand. 1994. Prolonged release from the airway tissue of glucocorticoids budesonide and fluticasone propionate as compared to beclomethasone dipropionate and hydrocortisone. Am. J. Respir. Crit. Care Med. 149: A466. (Abstr.)
7. Hoehberg, R. B., S. L. Pahuja, J. E. Zielinski, and J. M. Larner. 1991.Steroidal fatty acid esters. J. Steroid Biochem, Mol. Biol. 40: 577-585.
8. Mellon-Nussbaum, S., L. Ponticorvo, and S. Lieberman. 1979. Characterization of the lipoidal derivatives of pregnenolone prepared by incubation of the steroid with adrenal mitochondria. J. Biol. Chem. 254: 12500-12505.
9. Poulin. R., D. Poirier, C. Theriault, J. Couture, A. Belanger, and F. Labrie. 1990. Wide spectrum of steroids serving as substrates lor the formation of lipoidal derivatives in ZR-75-1 human breast eaneer cells. J. Steroid Biochem. Mol. Biol. 35: 237-247.
10. 3H]corticosterone hy acini from mammary gland of lactating rats. J. Biol. Chem. 253: 8545-8553.
11. Brattsand, R., and B. Axelsson. 1992. New inhaled glucocorticosteroids. In New Drugs for Asthma. Vol. 2. P. J. Barnes, editor. IBC Technical Services. London. 193-208.
12. Jonat, C., H. J. Rahmsdorf, K. K. Park, A. C. Cato, S. Gebel, H. Ponta, and P. Herrlich. 1990. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62: 1189-1204.
13. Barnes, P., and S. Pedersen. 1993. Efficacy and safety of inhaled corticosteroids in asthma. Am. Rev. Respir. Dis. 148(Suppl.): S1-S26.
14. Topp, W. C. 1981. Normal rat cell lines deficient in nuclear thymidine kinase. Virology 113: 408-411.
15. Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
16. Brattsand, R. 1997. What factors determine anti-inflammatory activity and selectivity of inhaled steroids. Eur. Respir. Rev. 7: 356-361.
17. Phillips, G. H. 1990. Structure-activity relationship of topically active steroids: the selection of fluticasone propionate. Respir. Med. 84(Suppl. A): 19-23.
18. Ek, A., B. M. Larsson, L. Palmberg, and K. Larsson. 1996. Glucocorticoids inhibit the release of cytokines from epithelial cells. Eur. Respir. J. 9(Suppl. 23): 126S.
19. Corrigan, C. J., J. K. Bungre, B. Assoufi, A. E. Cooper, H. Seddon, and A. B. Kay. 1996. Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. Eur. Respir. J. 9: 2077-2086.
20. Roca-Ferrer, J., J. Mullol, E. Lopez, A. Xaubet, L. Pujols, J. C. Fernandez, and C. Picado. 1997. Effect of topical anti-inflammatory drugs on epithelial cell-induced eosinophil survival and GM-CSF secretion. Eur. Respir. J. 10: 1489-1495.
21. Barnes, N., C. Hallett, and T. A. J. Harris. 1996. An overview of morning peak expiratory flow rate (PEFR) for clinical trials comparing fluticasonc propionate with budesonide. Eur. Respir. J. 9(Suppl. 23): 52S.
22. Agertoft, L., and S. Pedersen. 1997. A randomized double blind dose reduction study to compare the minimal effective dose of budesonide Turbu-haler and fluticasone propionate Diskhaler. J. Allergy Clin. Immunol. 99: 773-780.
23. McFadden, E. R., Jr. 1997. Budesonide Turbuhaler once daily administration for patients with mild to moderate chronic asthma. Am. J. Respir. Crit. Cure Med. 155(Suppl. 4. Pt. 2): A352. (Abstr.)
24. Venables, T. L., M. B. Addlerslone, A. J. Smithers, M. D. Blagden, D. Weston, T. Gooding, E. P. Carr, and R. M. Follows. 1996. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbu-haler and twice daily fluticasonc propionate via disc-haler at an equal dose of 400 mcg in adult asthmatics. Br. J. Clin. Res. 7: 15-32.
25. Billheimer, J. T., and P. J. Gillies. 1990. Intracellular cholesterol esterification. In Advances in Cholesterol Research. M. Esfahani and J. B. Swaney. editors. The Telford Press, Caldwell, NJ. 7-145.
26. Pahuja, S. L., and R. B. Hochberg. 1995. A comparison of the esterification of steroids by rat lecithin: cholesterol acyltransferase and acyl coenzyme Axholesteroi acyltransferase. Endocrinology 136: 180-186.
27. Tsujita, T., K. Shirai, Y. Saito, and H. Okuda. 1990. Relationship between lipase and esterase. In Isozyrnes: Structure, Function, and Use in Biology and Medicine. Wiley-Liss. Inc. New York, NY. 915-933.
28. Petrazzuoli, M., S. L. Pahuja, J. M. Larner, and R. B. Hochherg. 1990. Biological activity of the fatty acid ester metabolites of corticoids. Endocrinology 127: 555-559.
29. Zielinski, J. E., S. L. Pahuja. J. M. Larner, and R. M. Hochberg. 1991. Estrogenic action of estriol fatty acid esters. J. Steroid Biochem. Mol. Biol. 38: 399-405.
30. MacLusky, N. J., J. M. Larner, and R. Hochberg. 1989. Actions of estradiol-17-fatty acid ester in estrogen target tissue of the rat: comparison with other C-17 metabolites and a pharmacological C-17 ester. Endocrinology 124: 318-324.
31. Larner, J. M., N. J. MacLusky, and R. B. Hochberg. 1985. The naturally occuring C-17 fatty acid esters of estradiol are long-acting estrogens. J. Steroid Biochem. Mol. Hiol. 22: 407-413.
32. Miller-Larsson, A., P. Jansson, A. Runström, A.-B. Jeppsson, and R. Brattsand. 1997. Reversible fatty acid conjugation of hudesonide results in a prolonged topical anti-inflammatory activity in airways as compared to fluticasone propionate. Am. J. Respir. Crit. Care Med. 155: A353. (Abstr.)